{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:25:37Z","timestamp":1790058337598,"version":"4.0.1"},"reference-count":43,"publisher":"Impact Journals, LLC","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,4,13]]},"DOI":"10.18632\/oncotarget.24744","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T09:50:43Z","timestamp":1523613043000},"page":"20075-20088","source":"Crossref","is-referenced-by-count":112,"title":["S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth"],"prefix":"10.18632","volume":"9","author":[{"given":"Patrick","family":"Casara","sequence":"first","affiliation":[{"name":"Institut de Recherches Servier Discovery Chemistry Unit, Croissy Sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Davidson","sequence":"additional","affiliation":[{"name":"Vernalis (R&D) Ltd., Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Claperon","sequence":"additional","affiliation":[{"name":"Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebtane","family":"Le Toumelin-Braizat","sequence":"additional","affiliation":[{"name":"Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Vogler","sequence":"additional","affiliation":[{"name":"Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Bruno","sequence":"additional","affiliation":[{"name":"Institut de Recherches Internationales Servier, Oncology R&D Unit, Suresnes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00efa","family":"Chanrion","sequence":"additional","affiliation":[{"name":"Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Lysiak-Auvity","sequence":"additional","affiliation":[{"name":"Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Le Diguarher","sequence":"additional","affiliation":[{"name":"Institut de Recherches Servier Discovery Chemistry Unit, Croissy Sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me-Beno\u00eet","family":"Starck","sequence":"additional","affiliation":[{"name":"Institut de Recherches Servier Discovery Chemistry Unit, Croissy Sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ijen","family":"Chen","sequence":"additional","affiliation":[{"name":"Vernalis (R&D) Ltd., Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Whitehead","sequence":"additional","affiliation":[{"name":"Vernalis (R&D) Ltd., Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Graham","sequence":"additional","affiliation":[{"name":"Vernalis (R&D) Ltd., Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Matassova","sequence":"additional","affiliation":[{"name":"Vernalis (R&D) Ltd., Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Dokurno","sequence":"additional","affiliation":[{"name":"Vernalis (R&D) Ltd., Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Pedder","sequence":"additional","affiliation":[{"name":"Vernalis (R&D) Ltd., Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youzhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Qiu","sequence":"additional","affiliation":[{"name":"Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Girard","sequence":"additional","affiliation":[{"name":"Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Schneider","sequence":"additional","affiliation":[{"name":"Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Grav\u00e9","sequence":"additional","affiliation":[{"name":"Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Studeny","sequence":"additional","affiliation":[{"name":"Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghislaine","family":"Guasconi","sequence":"additional","affiliation":[{"name":"Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rocchetti","sequence":"additional","affiliation":[{"name":"Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Ma\u00efga","sequence":"additional","affiliation":[{"name":"CRCINA, INSERM, CNRS, Universit\u00e9 de Nantes, CHU de Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Henlin","sequence":"additional","affiliation":[{"name":"Institut de Recherches Servier Discovery Chemistry Unit, Croissy Sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Colland","sequence":"additional","affiliation":[{"name":"Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Kraus-Berthier","sequence":"additional","affiliation":[{"name":"Institut de Recherches Internationales Servier, Oncology R&D Unit, Suresnes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[{"name":"CRCINA, INSERM, CNRS, Universit\u00e9 de Nantes, CHU de Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.S.","family":"Dyer","sequence":"additional","affiliation":[{"name":"Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick","family":"Hubbard","sequence":"additional","affiliation":[{"name":"Vernalis (R&D) Ltd., Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Wood","sequence":"additional","affiliation":[{"name":"Vernalis (R&D) Ltd., Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Amiot","sequence":"additional","affiliation":[{"name":"CRCINA, INSERM, CNRS, Universit\u00e9 de Nantes, CHU de Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald M","family":"Cohen","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Hickman","sequence":"additional","affiliation":[{"name":"Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Morris","sequence":"additional","affiliation":[{"name":"Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Murray","sequence":"additional","affiliation":[{"name":"Vernalis (R&D) Ltd., Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Geneste","sequence":"additional","affiliation":[{"name":"Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,4,13]]},"reference":[{"key":"1","first-page":"7","article-title":"Cell Death Signaling","author":"Llambi","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Weinberg","year":"2011","journal-title":"Cell"},{"key":"3","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.6093263","article-title":"Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation","volume":"226","author":"Croce","year":"1984","journal-title":"Science"},{"key":"4","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1126\/science.6610211","article-title":"Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation","volume":"224","author":"Croce","year":"1984","journal-title":"Science"},{"key":"5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Adams","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Vaux","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Strasser","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1101\/gad.276725.115","article-title":"Inactivation of prosurvival Bcl-2 proteins activates Bax\/Bak through the outer mitochondrial membrane","volume":"30","author":"Luo","year":"2016","journal-title":"Genes Dev"},{"key":"9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cell.2012.12.031","article-title":"Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis","volume":"152","author":"Colman","year":"2013","journal-title":"Cell"},{"key":"10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Souers","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Korsmeyer","year":"2005","journal-title":"Nature"},{"key":"12","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Elmore","year":"2010","journal-title":"Lancet Oncol"},{"key":"13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"McKeegan","year":"2012","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Xiao","year":"2008","journal-title":"Cancer Res"},{"key":"15","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span","volume":"128","author":"Kile","year":"2007","journal-title":"Cell"},{"key":"16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Jin","year":"2013","journal-title":"Nat Med"},{"key":"17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Mobasher","year":"2016","journal-title":"Lancet Oncol"},{"key":"18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bmcl.2008.10.113","article-title":"Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors","volume":"19","author":"Stubberfield","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"19","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/cdd.2013.79","article-title":"Evaluation and critical assessment of putative MCL-1 inhibitors","volume":"20","author":"Cohen","year":"2013","journal-title":"Cell Death Differ"},{"key":"20","unstructured":"Le Diguarher, Casara, Starck, Henlin, Davidson, Murray, Graham, Chen, Geneste, Hickman, Depil, Le Tiran, Nyerges, et al. New indolizine compounds, a process for their preparation and pharmaceutical compositions containing them. 01\/08\/2013; WO2013110890A1."},{"key":"21","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1021\/ci100125a","article-title":"Enthalpic efficiency of ligand binding","volume":"50","author":"Keseru","year":"2010","journal-title":"J Chem Inf Model"},{"key":"22","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","article-title":"BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia","volume":"111","author":"Letai","year":"2008","journal-title":"Blood"},{"key":"23","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-07-4622","article-title":"Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models","volume":"14","author":"Tahir","year":"2008","journal-title":"Clin Cancer Res"},{"key":"24","first-page":"113","article-title":"The ability of Bcl-x(L) and Bcl-2 to prevent apoptosis can be differentially regulated","volume":"3","author":"Thompson","year":"1996","journal-title":"Cell Death Differ"},{"key":"25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1172\/JCI28281","article-title":"Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737","volume":"117","author":"Letai","year":"2007","journal-title":"J Clin Invest"},{"key":"26","doi-asserted-by":"publisher","first-page":"8750","DOI":"10.18632\/oncotarget.3275","article-title":"Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma","volume":"6","author":"Amiot","year":"2015","journal-title":"Oncotarget"},{"key":"27","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood.V99.7.2285","article-title":"The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile","volume":"99","author":"Chan","year":"2002","journal-title":"Blood"},{"key":"28","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1200\/JCO.2005.03.4264","article-title":"BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma","volume":"24","author":"Ott","year":"2006","journal-title":"J Clin Oncol"},{"key":"29","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1182\/blood.V87.3.1140.bloodjournal8731140","article-title":"Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia","volume":"87","author":"Campana","year":"1996","journal-title":"Blood"},{"key":"30","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2006-02-004234","article-title":"Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53","volume":"109","author":"Gjertsen","year":"2007","journal-title":"Blood"},{"key":"31","first-page":"219","article-title":"A comparison of three semiquantitation techniques","volume":"113","author":"Greil","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"32","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1073\/pnas.0800121105","article-title":"MiR-15a and miR-16-1 cluster functions in human leukemia","volume":"105","author":"Rassenti","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"33","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Volinia","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1158\/2159-8290.CD-12-0012","article-title":"Circumventing cancer drug resistance in the era of personalized medicine","volume":"2","author":"Janne","year":"2012","journal-title":"Cancer Discov"},{"key":"35","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2014-03-560284","article-title":"Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma","volume":"123","author":"Martinez-Climent","year":"2014","journal-title":"Blood"},{"key":"36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/s12885-017-3383-5","article-title":"Potential mechanisms of resistance to venetoclax and strategies to circumvent it","volume":"17","author":"Lam","year":"2017","journal-title":"BMC Cancer"},{"key":"37","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia","volume":"6","author":"Wood","year":"2016","journal-title":"Sci Rep"},{"key":"38","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nchembio.1246","article-title":"Structure-guided design of a selective BCL-X(L) inhibitor","volume":"9","author":"Kersten","year":"2013","journal-title":"Nat Chem Biol"},{"key":"39","doi-asserted-by":"crossref","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","volume":"7","author":"Chen","year":"2015","journal-title":"Sci Transl Med"},{"key":"40","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Paczal","year":"2016","journal-title":"Nature"},{"key":"41","doi-asserted-by":"crossref","first-page":"e1590","DOI":"10.1038\/cddis.2014.561","article-title":"Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)","volume":"6","author":"Bruncko","year":"2015","journal-title":"Cell Death Dis"},{"key":"42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ab.2004.05.055","article-title":"Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization","volume":"332","author":"Wang","year":"2004","journal-title":"Anal Biochem"},{"key":"43","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Murray","year":"2012","journal-title":"Nature"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T14:11:32Z","timestamp":1594822292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,13]]},"references-count":43,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2018,4,13]]}},"alternative-id":["24744","29732004"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.24744","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733195460.793566263","asserted-by":"object"}]},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,13]]}}}